Dynamic Coagulation Function Changes in COVID-19 Survivors With Coronary Artery Disease
Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32
DOI: 10.1177/10760296261476826 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 06.08.2026. Verfasst von Jianjun Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China. Hauptthemen laut MEDLINE: Coronary Artery Disease, COVID-19, Blood Coagulation, SARS-CoV-2. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Minsheng Research Project of Pudong New Area Science and Technology Development Fund.
Abstract (Originalsprache)
Coronary artery disease (CAD) and Coronavirus disease 2019 (COVID-19) are both associated with a hypercoagulable state, yet the long-term interaction between these prothrombotic conditions remains poorly characterized. This study investigated dynamic changes in coagulation function among COVID-19 survivors with CAD over a two-year follow-up period. A total of 117 CAD patients admitted to Shanghai Pudong Hospital between March and June 2022 were retrospectively enrolled: 60 with confirmed COVID-19 infection (COVID-19 group) and 57 without COVID-19 (control group). Thromboelastography (TEG) and conventional coagulation tests were performed at admission and at one and two years after discharge. Results showed that at one and two years after discharge, the COVID-19 group exhibited a comprehensive TEG profile indicative of a hypercoagulable state—including accelerated clot initiation, rapid propagation, and enhanced clot strength— compared to the control group (P < 0.05). In contrast, no significant between-group differences were observed in conventional coagulation parameters (P > 0.05). Notably, neutrophil levels in the COVID-19 group were significantly elevated at one and two years after discharge (P = 0.0353 and P = 0.0397, respectively) compared to acute-phase levels, while lymphocyte and platelet counts remained stable. Stratified analysis by antithrombotic intensity further revealed that standard antithrombotic regimens did not fully normalize the TEG-defined hypercoagulability in COVID-19 survivors at two-year follow-up. In conclusion, CAD patients with prior COVID-19 infection demonstrate sustained hypercoagulability and elevated neutrophil levels up to two years after discharge. These findings highlight the importance of TEG-based coagulation monitoring and neutrophil surveillance in CAD patients recovering from COVID-19 and support the need for individualized anticoagulation strategies. Future research should validate these findings in larger, multicenter cohorts and explore the underlying mechanisms and potential therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
- The College of Medical Technology, Shanghai University of Medicine and Health Sciences, Shanghai, China.
ORCID-Profile: Jianjun Zhang
Förderung
- Minsheng Research Project of Pudong New Area Science and Technology Development Fund
Zitieren
APA
Zhang, J., Yin, J., Jin, Y., Qian, Z., & Chen, Y. (2026). Dynamic Coagulation Function Changes in COVID-19 Survivors With Coronary Artery Disease. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261476826
Vancouver
Zhang J, Yin J, Jin Y, Qian Z, Chen Y. Dynamic Coagulation Function Changes in COVID-19 Survivors With Coronary Artery Disease. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261476826
BibTeX
@article{Zhang2026,
author = {Zhang, Jianjun and Yin, Junqi and Jin, Yucheng and Qian, Zhe and Chen, Youyou},
title = {Dynamic Coagulation Function Changes in COVID-19 Survivors With Coronary Artery Disease},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2026},
volume = {32},
doi = {10.1177/10760296261476826}
}
EUVIMED